Loading...

Cotinga Pharmaceuticals Inc.

COTQF•PNK
HealthcareBiotechnology
$0.001
$0.00(400.000%)

Cotinga Pharmaceuticals Inc. (COTQF) Stock Overview

Explore Cotinga Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for COTQFStats details for COTQF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for COTQFAnalyst Recommendations details for COTQF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

CEO

Dr. Richard T. Ho

Headquarters

The Canadian Venture Building, Toronto, ON

Founded

2009

Frequently Asked Questions